Navigation Links
Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Date:8/8/2014

LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives. 

According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market.  In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.

"Promescent may seem like a miracle, but it is actually just great science," says Abraham.  "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation.  This means men are not deprived of sensation and neither are their partners."

Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:

http://www.kfiam640.com/media/podcast-john-and-ken-on-demand-JohnandKen/jane-wells-cnbc-6pm-86-25128155/

Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.

"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham.  "This helps men better satisfy their partners and gain sexual confidence."

Promescent is available on-line and over-the-counter at independent pharmacies across the nation.  It is safe, effective, and doctor recommended. 

For more information, please visit http://www.promescent.com/.

To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
5. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
6. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
7. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
8. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
(Date:9/6/2017)... Sept. 6, 2017  Robert G. Szewc, M.D., is ... Member in recognition of his contributions to the Medical ... a Nephrologist at the practice of Kidney and Hypertension ... care and hypertension solutions. He has worked in this ... career experience, as well as expertise in kidneys, hypertension, ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers ... Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence ... Athletic Trainers are acknowledged by their peers with accolades and highly prestigious awards. ...
(Date:9/20/2017)... Georgia (PRWEB) , ... September 20, 2017 , ... ... new digital and social campaign, “Humans With Vaginas.” The goal is to ignite ... importance of non-toxic personal care products. The brand has declared September “Humans with ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and ... that it will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital ... three live 60-minute complimentary webinars on October 17, 2017 at 2 P.M. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) ... HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, 2017 to assist ... offering these discounted prices to all businesses and government agencies – whether or not ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “The Trials ... trials and tribulations as he emotionally pens his aspirations and goals to better one’s ... of published author, Jimmy Green, while searching in all the wrong places, found a ...
Breaking Medicine News(10 mins):